Author

V. Amo-Addae

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

J. J. Molenaar· 2 shared S. Eising· 2 shared D. J. Munter· 1 shared D. Wilbie· 1 shared E. Bosman· 1 shared E. Duiker· 1 shared E. Mastrobattista· 1 shared F. Ringnalda· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

J. J. Molenaar

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out

D. Wilbie, S. Eising, V. Amo-Addae, J. Walther, E. Bosman, O. G. de Jong, J. J. Molenaar, E. Mastrobattista

This study screens cancer drugs to find those that enhance HDR over NHEJ in CRISPR gene editing, identifying Aurora kinase A inhibitors as promising candidates.

PLOS One · Sep 26, 2025Peer-reviewedPharmacology & Toxicology

Multi-dimensional profiling of hepatoblastomas and patient-derived tumor organoids uncovers tumor subpopulations with divergent WNT activation profiles and identifies pan-hepatoblastoma drug sensitivities

T. A. Kluiver, Y. Lu, S. A. Schubert, L. J. Kraaier, F. Ringnalda, P. Lijnzaad, J. DeMartino, W. L. Megchelenbrink, V. Amo-Addae, S. Eising, F. W. de Faria, D. J. Munter, M. van de Wetering, K. Kerl, E. Duiker, , W. C. Peng

This study identifies two hepatoblastoma subtypes with distinct WNT activation profiles and discovers drug sensitivities in patient-derived tumor organoids.

bioRxiv · Aug 28, 2023 · PreprintCancer Biology